A 32-year-old man from Delhi presents with a 3-week history of productive cough, fever, and night sweats. Chest X-ray shows a cavitary lesion in the right upper lobe. Sputum smear microscopy is positive for acid-fast bacilli (AFB). He is diagnosed with pulmonary tuberculosis and started on standard first-line anti-TB therapy (HRZE). After 2 months of treatment, repeat sputum smear microscopy remains positive. What is the most appropriate next step in management?

Explanation

## Clinical Context A patient with microbiologically-confirmed pulmonary TB who remains sputum-positive after 2 months of standard first-line therapy is classified as a **treatment failure** and raises concern for drug-resistant tuberculosis (DR-TB). ## Key Point: **Persistent sputum positivity beyond 2 months of HRZE therapy mandates investigation for drug resistance.** Culture and DST are the gold standard to identify the resistance pattern (MDR-TB, XDR-TB, or other) before escalating therapy. ## Rationale for Next Step According to WHO and Indian TB guidelines (NTEP), the management algorithm for treatment failure is: 1. **Confirm microbiological failure** — repeat sputum smear (already done; still positive) 2. **Investigate for drug resistance** — send sputum for culture and DST 3. **Assess adherence** — rule out non-adherence as a cause 4. **Escalate therapy** — only after DST results guide the choice of second-line drugs ## High-Yield: **Blind escalation to second-line drugs without DST is inappropriate and risks: - Unnecessary exposure to more toxic agents - Incorrect drug selection if resistance pattern is unknown - Worsening outcomes if the patient is actually non-adherent (not truly resistant)** ## Clinical Pearl: In India, approximately 2–3% of new TB cases and 10–15% of previously treated cases have MDR-TB. DST is mandatory before switching regimens to ensure targeted therapy. ## Table: Treatment Failure vs. Other Scenarios | Scenario | Sputum Status at 2 Months | Next Step | | --- | --- | --- | | **Treatment success** | Negative | Continue standard therapy (4 months more) | | **Treatment failure** | Positive | Culture + DST; assess adherence | | **Non-adherence (no resistance)** | Positive | Counsel + directly observed therapy (DOT); repeat smear at 1 month | | **Confirmed DR-TB** | Positive | Switch to appropriate second-line regimen based on DST | [cite:NTEP Guidelines 2022, Harrison 21e Ch 158]